Replies to post #140114 on Bioelectronics Corp (BIEL)

[Simpsonly]

Seems to me, sausage, that Boots will make a lot less revenue receiving only the NHS approved dispensing fee for an ActiPatch, as compared to the 50% plus/minus margin on an OTC sale. There are also different ramifications on purchasing, IMS and Rx fulfillment. Perhaps Boots decided, ‘why do both?’ knowing that Rx sales of NHS subsidized sales nationally are going north, while OTC sales could only go south? I’ll take the NHS route every time!